Adding exenatide to metformin significantly improved blood sugar, blood lipids, liver enzymes, and gut microbiome composition in type 2 diabetes patients with fatty liver disease over 24 weeks.
All markers improved (p<0.001)Blood glucose, lipids, and liver enzymes all improved significantly with exenatide plus metformin versus metformin alone, with additional beneficial shifts in gut bacteria.
What the researchers found
After 24 weeks, exenatide plus metformin (Group B) was significantly superior to metformin alone (Group A) across all measured outcomes: fasting blood glucose, postprandial glucose, triglycerides, total cholesterol, ALT, and AST were all lower in the combination group (p<0.001 for all).
The combination also significantly improved intestinal flora: counts of harmful bacteria (E. coli and Enterococcus faecalis) were lower (p<0.05), while beneficial bacteria (Bifidobacteria and Lactobacillus) were higher (p<0.05) in the combination group. This suggests exenatide and metformin have synergistic effects on metabolic, hepatic, and microbiome parameters.
Why it matters
Type 2 diabetes and fatty liver disease frequently coexist, and treating both simultaneously is a clinical priority. This study shows that adding a GLP-1 peptide drug (exenatide) to standard metformin therapy provides comprehensive improvement — not just better blood sugar, but also liver protection and a healthier gut microbiome. The gut flora changes suggest a novel mechanism through which GLP-1 drugs may benefit liver health.
How the study worked
This was a randomized controlled trial of 128 type 2 diabetes patients with non-alcoholic fatty liver disease, diagnosed between January 2019 and January 2022. Patients were randomly assigned to metformin alone (n=64) or exenatide injection plus metformin (n=64) for 24 weeks. Outcomes included fasting and postprandial blood glucose, triglycerides, total cholesterol, liver enzymes (ALT, AST), and stool samples for intestinal flora analysis.
What this study cannot tell us
The study was open-label (not blinded), which could introduce bias in subjective assessments. It was conducted at a single center with a relatively homogeneous population. The abstract doesn't report specific numerical values for outcomes, making it hard to assess the magnitude of differences. The gut flora analysis appears limited to specific cultured species rather than comprehensive metagenomic sequencing. No liver imaging endpoints were reported.
How to read the evidence
This is a randomized controlled trial with a reasonable sample size (128 patients) and 24-week duration. However, it was open-label and single-center, and the abstract lacks specific numerical outcome data, which limits the ability to assess effect sizes.
When this study was published
Published in 2024 with data collected from 2019-2022, this study reflects growing interest in the multi-system effects of GLP-1 drugs, including their impact on the gut microbiome in the context of metabolic liver disease.
The bigger picture
The gut-liver-metabolic axis is increasingly recognized as central to diabetes and fatty liver disease. This study adds clinical evidence that GLP-1 peptide drugs like exenatide may work partly by reshaping gut flora — not just through direct hormonal effects. As the field moves toward understanding how incretin therapies affect the microbiome, these findings contribute to a more complete picture of why these drugs have such broad metabolic benefits.
Questions still open
- Does the gut microbiome improvement drive the liver enzyme improvements, or are these parallel effects of exenatide?
- Would newer GLP-1 drugs like semaglutide produce even greater improvements in gut flora and liver function?
- Do the microbiome changes persist after stopping exenatide, or does the flora revert?
Common questions
Why would a diabetes drug also improve gut bacteria?
What is the connection between diabetes, fatty liver, and gut bacteria?
Read the original research
Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
JPMA. The Journal of the Pakistan Medical Association, 74(1), 138-140
Citation
Jiang, Xiaojie; Shi, Tingting; Han, Dan; Chen, Juan. (2024). Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.. JPMA. The Journal of the Pakistan Medical Association, 74(1), 138-140. https://doi.org/10.47391/JPMA.8295